Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Troriluzole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biohaven Achieves Topline Results in Study of Troriluzole in SCA
    Biohaven Achieves Topline Results in Study of Troriluzole in SCA

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia-sca-302255056.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share
    Biohaven To Discuss Topline Results in Spinocerebellar Ataxia
    Biohaven To Discuss Topline Results in Spinocerebellar Ataxia

    20 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-spinocerebellar-ataxia-302254638.html

    PR NEWSWIRE
    20 Sep 2024
    Share Share
    A blow for Biohaven as FDA refuses failed rare disease drug
    A blow for Biohaven as FDA refuses failed rare disease drug

    27 Jul 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/further-blow-biohaven-fda-refuses-consider-failed-rare-disease-drug-approval

    James Waldron FIERCE BIOTECH
    27 Jul 2023
    Share Share
    Biohaven adds to a long list of Alzheimer's drug failures
    Biohaven adds to a long list of Alzheimer's drug failures

    20 Jan 2021

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/biohaven-adds-to-a-long-list-of-alzheimers-drug-failures/593578/

    Jacob Bell BIOPHARMADIVE
    20 Jan 2021
    Share Share
    MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)
    MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)

    19 Jan 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/01/18/2160200/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-the-Combination-of-MN-166-ibudilast-and-Riluzole-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Japan.html

    GLOBENEWSWIRE
    19 Jan 2021
    Share Share
    Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive
    Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive

    04 Jan 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-begins-pivotal-phase-3-trial-of-troriluzole-in-obsessive-compulsive-disorder-301199932.html

    PRNEWSWIRE
    04 Jan 2021
    Share Share